Abbott Laboratories (NYSE:ABT) received CE Mark for its Cologuard Plus colorectal cancer test under the EU In Vitro ...

The Cologuard Plus home screening test [Image courtesy of Abbott/Exact Sciences]Abbott (NYSE: ABT) has received approval in ...

Only Abbott offers a complete screening solution combining end-to-end support with both stool- and blood-based colorectal cancer screening options, giving healthcare providers more ways to help ...

Abbott said its 15-minute, hand-held blood test could help rule out the need for imaging scans to check for tissue damage in the 24 hours following a possible concussion or traumatic brain injury.

Abbott's lab-based concussion test looks for two biomarkers in the blood, both of which have been closely linked to traumatic brain injuries when found in elevated concentrations. In studies, it was ...

CE Mark is an important regulatory milestone as Abbott prepares to introduce Cologuard Plus in select European markets, with timing and availability varying by country.